244 related articles for article (PubMed ID: 26044462)
21. Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 3: Design considerations.
Ball G; Silverman MH
Contemp Clin Trials; 2011 Sep; 32 Suppl 1():S8-10. PubMed ID: 21664988
[TBL] [Abstract][Full Text] [Related]
22. Design issues in initial HIV-treatment trials: focus on ACTG A5095.
Ribaudo HJ; Kuritzkes DR; Schackman BR; Acosta EP; Shikuma CM; Gulick RM
Antivir Ther; 2006; 11(6):751-60. PubMed ID: 17310819
[TBL] [Abstract][Full Text] [Related]
23. Changes in beliefs identify unblinding in randomized controlled trials: a method to meet CONSORT guidelines.
Rees JR; Wade TJ; Levy DA; Colford JM; Hilton JF
Contemp Clin Trials; 2005 Feb; 26(1):25-37. PubMed ID: 15837450
[TBL] [Abstract][Full Text] [Related]
24. The landscape and lexicon of blinding in randomized trials.
Schulz KF; Chalmers I; Altman DG
Ann Intern Med; 2002 Feb; 136(3):254-9. PubMed ID: 11827510
[No Abstract] [Full Text] [Related]
25. A critique of the double-blind clinical trial. Part 1.
Kiene H
Altern Ther Health Med; 1996 Jan; 2(1):74-80. PubMed ID: 8795875
[TBL] [Abstract][Full Text] [Related]
26. Clinical trial design issues: at least 10 things you should look for in clinical trials.
Glasser SP; Howard G
J Clin Pharmacol; 2006 Oct; 46(10):1106-15. PubMed ID: 16988199
[TBL] [Abstract][Full Text] [Related]
27. Blinding in randomised trials: hiding who got what.
Schulz KF; Grimes DA
Lancet; 2002 Feb; 359(9307):696-700. PubMed ID: 11879884
[TBL] [Abstract][Full Text] [Related]
28. Commentary on Reconstituting Fibrinogen Concentrate to Maintain Blinding in a Double-blind, Randomized Trial in an Emergency Setting.
Bruynseels D; Solomon C; Hallam A; Collins PW; Collis RE; Hamlyn V; Hall JE
J Emerg Med; 2016 Jan; 50(1):104-7.e1. PubMed ID: 26508700
[TBL] [Abstract][Full Text] [Related]
29. Unreported formal assessment of unblinding occurred in 4 of 10 randomized clinical trials, unreported loss of blinding in 1 of 10 trials.
Bello S; Moustgaard H; Hróbjartsson A
J Clin Epidemiol; 2017 Jan; 81():42-50. PubMed ID: 27555081
[TBL] [Abstract][Full Text] [Related]
30. Design considerations for randomised trials in orthopaedic fracture surgery.
Simunovic N; Devereaux PJ; Bhandari M
Injury; 2008 Jun; 39(6):696-704. PubMed ID: 18502423
[TBL] [Abstract][Full Text] [Related]
31. How well does blinding work in randomized controlled trials?: a counterpoint.
Boehmer J; Yong P
Clin Pharmacol Ther; 2009 May; 85(5):463-5. PubMed ID: 19381149
[No Abstract] [Full Text] [Related]
32. Ethics, consent and blinding: lessons from a placebo/sham controlled CPAP crossover trial.
Djavadkhani Y; Marshall NS; D'Rozario AL; Crawford MR; Yee BJ; Grunstein RR; Phillips CL
Thorax; 2015 Mar; 70(3):265-9. PubMed ID: 25595508
[TBL] [Abstract][Full Text] [Related]
33. DEPERROR: Risks of systematic errors in drug and non-drug randomized clinical trials assessing intervention effects in patients with unipolar depression.
Krogh J; Hjorthøj CR; Jakobsen JC; Lindschou J; Kessing LV; Nordentoft M; Gluud C
J Affect Disord; 2015 Jul; 179():121-7. PubMed ID: 25863907
[TBL] [Abstract][Full Text] [Related]
34. Entanglement, knowledge, and their possible effects on the outcomes of blinded trials of homeopathic provings.
Milgrom LR
J Altern Complement Med; 2006 Apr; 12(3):271-9. PubMed ID: 16646726
[TBL] [Abstract][Full Text] [Related]
35. The risk of unblinding was infrequently and incompletely reported in 300 randomized clinical trial publications.
Bello S; Moustgaard H; Hróbjartsson A
J Clin Epidemiol; 2014 Oct; 67(10):1059-69. PubMed ID: 24973822
[TBL] [Abstract][Full Text] [Related]
36. The design of randomized controlled trials.
Curtis BM; Barrett BJ; Parfrey PS
Methods Mol Biol; 2009; 473():95-111. PubMed ID: 19160733
[TBL] [Abstract][Full Text] [Related]
37. Blinding of outcomes in trials of orthopaedic trauma: an opportunity to enhance the validity of clinical trials.
Karanicolas PJ; Bhandari M; Taromi B; Akl EA; Bassler D; Alonso-Coello P; Rigau D; Bryant D; Smith SE; Walter SD; Guyatt GH
J Bone Joint Surg Am; 2008 May; 90(5):1026-33. PubMed ID: 18451395
[TBL] [Abstract][Full Text] [Related]
38. Blinding: an essential component in decreasing risk of bias in experimental designs.
Forbes D
Evid Based Nurs; 2013 Jul; 16(3):70-1. PubMed ID: 23696228
[No Abstract] [Full Text] [Related]
39. Blinding, pragmatism, and the PRECIS-2 tool for designing and assessing randomized trials.
Zwarenstein M; Howie A
Eur J Clin Pharmacol; 2021 Jul; 77(7):1069-1070. PubMed ID: 33394054
[No Abstract] [Full Text] [Related]
40. Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 4: One method.
Ball G
Contemp Clin Trials; 2011 Sep; 32 Suppl 1():S11-7. PubMed ID: 21651993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
